Segment, Customer and Geographical Reporting (Tables)

9 Months Ended

Jun. 30, 2017

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The Company’s segment information for the three months ended June 30, 2017 and 2016 is summarized below:

Results of Operations for the Three Months Ended June 30,

2017

				Contract
	Optics			Research			Biomedical		Total
Revenue	$	4,837,000		$	3,999,000		$	-	$	8,836,000
Gross profit		1,655,000			1,709,000			-		3,364,000
GM %		34	%		43	%		-		38	%
Operating expenses		1,619,000			1,640,000			377,000		3,636,000
Operating income (loss)		36,000			69,000			(377,000)		(272,000)
Depreciation and amortization		248,000			52,000			1,000		301,000
Capital expenditures		179,000			54,000			26,000		259,000
Intangibles, net		468,000			205,000			394,000		1,067,000
Goodwill		955,000			4,939,000			-		5,894,000
Total assets	$	19,488,000		$	8,004,000		$	690,000	$	28,182,000

Results of Operations for the Three Months Ended June 30,

2016

				Contract
	Optics			Research			Biomedical		Total
Revenue	$	5,780,000		$	4,626,000		$	-	$	10,406,000
Gross profit		2,012,000			1,915,000			-		3,927,000
GM %		35	%		41	%		-		38	%
Operating expenses		1,604,000			1,601,000			396,000		3,601,000
Operating income (loss)		408,000			314,000			(396,000)		326,000
Depreciation and amortization		247,000			24,000			17,000		288,000
Capital expenditures		330,000			-			6,000		336,000
Intangibles, net		549,000			239,000			308,000		1,096,000
Goodwill		1,001,000			4,939,000			-		5,940,000
Total assets	$	16,752,000		$	8,546,000		$	424,000	$	25,722,000

The Company’s segment information for the nine months ended June 30, 2017 and 2016 is summarized below:

Results of Operations for the Nine Months Ended June 30,

2017

				Contract
	Optics			Research			Biomedical		Total
Revenue	$	14,524,000		$	13,541,000		$	-	$	28,065,000
Gross profit		5,144,000			5,535,000			-		10,679,000
GM %		35	%		41	%		-		38	%
Operating expenses		4,544,000			5,182,000			1,150,000		10,876,000
(Gain) loss on sale of assets		-			-			-		-
Operating income (loss)		600,000			353,000			(1,150,000)		(197,000)
Depreciation and amortization		719,000			200,000			7,000		926,000
Capital expenditures		373,000			88,000			72,000		533,000
Intangibles, net		468,000			205,000			394,000		1,067,000
Goodwill		955,000			4,939,000			-		5,894,000
Total assets	$	19,488,000		$	8,004,000		$	690,000	$	28,182,000

Results of Operations for the Nine Months Ended June 30,

2016

				Contract
	Optics			Research			Biomedical		Total
Revenue	$	18,415,000		$	14,484,000		$	-	$	32,899,000
Gross profit		6,330,000			5,639,000			-		11,969,000
GM %		34	%		39	%		-		36	%
Operating expenses		5,237,000			5,107,000			1,099,000		11,443,000
(Gain) loss on sale of assets		(4,000)			-			-		(4,000)
Operating income (loss)		1,097,000			532,000			(1,099,000)		530,000
Depreciation and amortization		700,000			187,000			52,000		939,000
Capital expenditures		1,224,000			37,000			81,000		1,342,000
Intangibles, net		549,000			239,000			308,000		1,096,000
Goodwill		1,001,000			4,939,000			-		5,940,000
Total assets	$	16,752,000		$	8,546,000		$	424,000	$	25,722,000

Schedule Of Segment Revenue By Geographical Location [Table Text Block]

Revenue by geographic location in total and as a percentage of total revenue, for the three months ended June 30, 2017 and 2016 are as follows:

	Three Months Ended					Three Months Ended
	June 30, 2017					June 30, 2016
Geographic Location	Revenue		% of Total			Revenue		% of Total
United States	$	6,928,000		78	%	$	7,908,000		76	%
Europe		962,000		11	%		1,868,000		18	%
Other		946,000		11	%		630,000		6	%
	$	8,836,000		100	%	$	10,406,000		100	%

Revenue by geographic location in total and as a percentage of total revenue, for the nine months ended June 30, 2017 and 2016 are as follows:

	Nine Months Ended					Nine Months Ended
	June 30, 2017					June 30, 2016
Geographic Location	Revenue		% of Total			Revenue		% of Total
United States	$	22,051,000		78	%	$	24,363,000		74	%
Europe		3,262,000		12	%		6,361,000		19	%
Other		2,752,000		10	%		2,175,000		7	%
	$	28,065,000		100	%	$	32,899,000		100	%